<DOC>
	<DOCNO>NCT01353391</DOCNO>
	<brief_summary>Insulin standard treatment management type 2 diabetes pregnancy , however despite treatment insulin , woman continue face increase rate adverse maternal fetal outcome . The investigator hypothesize metformin use , addition treatment insulin , help blood sugar control , low dose insulin need , low weight gain , improve baby outcome .</brief_summary>
	<brief_title>Metformin Women With Type 2 Diabetes Pregnancy Trial</brief_title>
	<detailed_description>Type 2 diabetes pregnancy increase prevalence woman continue face increase rate adverse maternal fetal outcome . The investigator hypothesize metformin use , adjunct insulin , decrease adverse outcome reduce maternal hyperglycemia , high maternal insulin dos , excessive maternal weight gain gestational hypertension/pre-eclampsia , reduce perinatal neonatal mortality morbidity . In addition , since metformin cross placenta , metformin treatment fetus may direct beneficial effect neonatal outcomes . This study randomize control trial ( RCT ) add metformin insulin , double-blind , placebo-controlled RCT . The investigator believe neither metformin alone insulin alone effectively treat population , therefore design , include addition metformin insulin , relevant patient .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pregnancy Diabetics</mesh_term>
	<mesh_term>Diabetes , Gestational</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Women 1845 year age . 2 . ( ) . Women diagnose type 2 diabetes prior pregnancy , OR ( ii ) . Women undiagnosed type 2 diabetes diagnose prior 20 week gestation , define woman present gestational diabetes 20 week gestation various combination , per Canadian Diabetes Association , include : 2 fast glucose ≥ 7.0 mmol/L , 2 HbA1c ≥0.065 ( 6.5 % ) perform laboratory use method standardize Diabetes Control Complications Trial ( DCCT ) assay , 1 fast glucose ≥7.0 mmol/L 1 HbA1c ≥ 0.065 ( 6.5 % ) perform laboratory use method standardize DCCT assay , 1 fast glucose ≥ 7.0 mmol/L 1 two hour ( 2 hr ) ≥ 11.1 75 g Oral Glucose Tolerance Test ( OGTT ) , 1 HbA1C ≥0.065 ( 6.5 % ) perform laboratory use method standardize DCCT assay 1 two hour ( 2 hr ) ≥ 11.1 75 g OGTT . 3 . Pregnancy gestation 6+022+6 week . 4 . Live singleton fetus . 1 . Women insulin . Women oral hypoglycemic agent take start trial start insulin prior randomization . 2 . Diabetes diagnose 20 week gestation . 3 . Type 1 diabetes . 4 . Known intolerance metformin . 5 . Contraindications metformin use include : ( ) . Renal insufficiency ( define serum creatinine great 130 µmol/L creatinine clearance &lt; 60 ml/min ) , ( ii ) . Moderate severe liver dysfunction ( define liver enzymes ( aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ) great 3 time upper limit normal ) , ( iii ) . Shock sepsis , ( iv . ) Previous hypersensitivity metformin . f. Women significant gastrointestinal problem severe vomit require IV fluid hospitalization , active Crohn 's colitis . g. Previous participation trial . h. Women fetus know potentially lethal anomaly exclude . Information regard congenital anomaly diagnose randomization record . . Known high order pregnancy ( twin , triplet , etc ) . These woman exclude high rate adverse outcome want avoid inequality unequally distribute group . j . Presence acute chronic metabolic acidosis , include diabetic ketoacidosis . k. History diabetic ketoacidosis history lactic acidosis . l. Presence excessive alcohol intake , acute chronic . m. Presence congestive heart failure history congestive heart failure .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>MiTy</keyword>
	<keyword>Metformin Women</keyword>
	<keyword>Type 2 Diabetes Pregnancy</keyword>
</DOC>